We serve Chemical Name:Methyl 2-(3-Hydroxycyclohexyl)acetate CAS:86576-86-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Methyl 2-(3-Hydroxycyclohexyl)acetate
CAS.NO:86576-86-5
Synonyms:Methyl 2-(3-Hydroxycyclohexyl)acetate
Molecular Formula:C9H16O3
Molecular Weight:172.22200
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:46.53000
Exact Mass:172.11000
LogP:1.10060
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Methyl 2-(3-Hydroxycyclohexyl)acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Methyl 2-(3-Hydroxycyclohexyl)acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methyl 2-(3-Hydroxycyclohexyl)acetate Use and application,Methyl 2-(3-Hydroxycyclohexyl)acetate technical grade,usp/ep/jp grade.
Related News: Biogen’s top research chief, Dr. Al Sandrock, defended the drug in an open letter released alongside the company’s earnings Thursday, saying its approval has been subject to “extensive misinformation and misunderstanding.” (S)-3-(4-fluoro-phenyl)-N-{1-[3-(pyrimidin-5-yloxy)-phenyl]-ethyl}-acrylamide manufacturers But one clear concern among the CDC’s expert group this time around was the rapidly spreading Delta variant, first found in India. That mutated strain now accounts for over 80% of new U.S. infections that are sequenced, CDC data shows. N-(2,6-Dimethyl-phenyl)-4-(2-oxo-1,2-dihydro-quinolin-6-yloxy)-butyramide suppliers “Partnering with a CDMO that has the skills and capabilities to execute a successful tech transfer is critical, as this complex, multi-step process helps lay the foundation for the new drug’s journey through to commercialization. N-(4-methyl-5-oxocyclopenten-1-yl)-2-aminobenzonitrile vendor & factory Biogen’s top research chief, Dr. Al Sandrock, defended the drug in an open letter released alongside the company’s earnings Thursday, saying its approval has been subject to “extensive misinformation and misunderstanding.”,Biogen’s top research chief, Dr. Al Sandrock, defended the drug in an open letter released alongside the company’s earnings Thursday, saying its approval has been subject to “extensive misinformation and misunderstanding.”
